Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 12 for:    TOTAL | Recruiting Studies | Interventional Studies | brentuximab
Previous Study | Return to List | Next Study

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03496779
Recruitment Status : Recruiting
First Posted : April 12, 2018
Last Update Posted : June 20, 2019
Sponsor:
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

Brief Summary:
This study is an open label, multicenter phase 2 study. The primary objective of the study is to determine the efficacy of brentuximab vedotin in patients treated by gemcitabine for relapsed or refractory peripheral T-cell lymphoma in term of overall response rate assessed after 4 cycles of treatment according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).

Condition or disease Intervention/treatment Phase
Refractory Peripheral T-Cell Lymphoma Relapsed Peripheral T-Cell Lymphoma Drug: Brentuximab Vedotin - induction Drug: Gemcitabine Drug: Brentuximab Vedotin - maintenance Procedure: autologous or allogeneic stem cell transplantation Phase 2

Detailed Description:

Currently, there is no standard treatment for patients with recurrent or refractory peripheral T-cell lymphoma who relapse after a first line of cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (CHOP) treatment.

Chemotherapies such as gemcitabine are used as monotherapy but the results alone are insufficient. In addition, there is no approved monotherapy in the European Union, with the exception of brentuximab vedotin in refractory or recurrent large systemic anaplastic lymphomas.

Stem cell transplantation may be an option for patients who respond to a second line of treatment or a subsequent line of treatment, but conditions for being eligible for transplantation, including long-term remission, are infrequent.

Brentuximab vedotin (BV) is a targeted treatment directed against a protein, cluster of differentiation antigen 30 (CD30), present on the surface of lymphoma cells. It allows chemotherapy to enter directly into the lymphoma cell. The CD30 protein is variably expressed in patients with relapsed or refractory T-cell lymphoma; about 50% of patients have significant expression.

Data from clinical studies with brentuximab vedotin suggest that the addition of this treatment to gemcitabine may be more successful than gemcitabine alone.

The main hypothesis is a 15% increase in responder patients after 4 cycles of treatment with brentuximab vedotin and gemcitabine. The main objective of the study is therefore to determine the overall response rate after 4 cycles of treatment according to the criteria of Lugano 2014 (response based on CT-scan).

The secondary objectives will focus on the efficacy of brentuximab vedotin: complete response rate, response time for responder patients, time to failure of treatment, time to next treatment and overall survival, efficacy of brentuximab vedotin maintenance: survival progression-free, response time, overall survival, overall response rate based on positron emission tomography (PET)-scan and brentuximab vedotin toxicity in patients treated with gemcitabine and in maintenance therapy.

The duration of the study is estimated to be 4.5 years including follow-up with an estimated recruitment period of 1.5 years. 70 patients will be enrolled.


Layout table for study information
Study Type : Interventional
Estimated Enrollment : 70 participants
Intervention Model: Single Group Assignment
Intervention Model Description: This study is an open label, multicenter phase 2 study. Patients treated with gemcitabine will receive brentuximab vedotin (GBv) for 4 cycles of induction.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance
Actual Study Start Date : April 10, 2018
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : October 2022


Arm Intervention/treatment
Experimental: Experimental

Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction.

Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation.

Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions.

Drug: Brentuximab Vedotin - induction
Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
Other Name: Adcetris

Drug: Gemcitabine
Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
Other Name: Gemzar

Drug: Brentuximab Vedotin - maintenance

Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.

Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy

Other Name: Adcetris

Procedure: autologous or allogeneic stem cell transplantation
Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation




Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: 16 weeks = 4 cycles or permanent treatment discontinuation ]
    rate of patient in Complete/Partial response according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).


Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: 16 weeks = 4 cycles or permanent treatment discontinuation ]
    % of patient who did not progressed according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).

  2. Progression-Free Survival (PFS) [ Time Frame: 4.5 years ]
    % of patient who did not progressed according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).

  3. Complete Response Rate (CRR) [ Time Frame: 16 weeks = 4 cycles or permanent treatment discontinuation ]
    rate of patient in Complete Response (CR)according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).

  4. Duration of Response (DoR) [ Time Frame: 16 weeks = 4 cycles or permanent treatment discontinuation ]
    duration between the Complete/Partial Response and the Progression according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response) = duration between the Complete/Partial Response and the Progression

  5. Duration of Response (DoR) [ Time Frame: 4.5 years ]
    duration between the Complete/Partial Response and the Progression according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response) = duration between the Complete/Partial Response and the Progression

  6. Time to Treatment Failure (TTF) [ Time Frame: 16 weeks = 4 cycles or permanent treatment discontinuation ]
    duration between the inclusion and the premature end of treatment

  7. Time to next treatment [ Time Frame: 16 weeks = 4 cycles or permanent treatment discontinuation ]
    Duration between the end of the studied treatment and the beginning of a new one after progression

  8. Overall Survival (OS) [ Time Frame: 16 weeks = 4 cycles or permanent treatment discontinuation ]
    % of patient still alive

  9. Overall Survival (OS) [ Time Frame: 4.5 years ]
    % of patient still alive

  10. Overall response rate [ Time Frame: 4.5 years ]
    rate of patient in Complete/Partial response according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).

  11. Number of Serious Adverse Events (SAE) during the induction period [ Time Frame: 16 weeks = 4 cycles or permanent treatment discontinuation ]
  12. Number of Serious Adverse Events (SAE) during the maintenance period [ Time Frame: 36 weeks = 12 cycles or permanent treatment discontinuation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females of 18 years to 80 years of age;
  • Understand and voluntarily sign an informed consent document prior to any study related assessment or procedure;
  • Patients able to adhere to the study visit schedule and protocol requirements;
  • Patients with histologically proven, CD30 positive (at least 5% of cells according to local examination) peripheral T-cell lymphoma (PTCL) according to the 2016 World Health Organization (WHO) classification for whom gemcitabine treatment is expected. A biopsy at relapse is highly recommended;
  • Patients who have evidence of relapsed disease after at least one line (and no more than three lines) of treatment or who were refractory to a first or subsequent line of treatment;
  • Patients with Ann Arbor stage I - IV;
  • Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2;
  • Patients with at least one measurable disease, i.e. one nodal or extra-nodal lesion of 1.5 cm or more;
  • Negative pregnancy test for females of childbearing potential (FCBP);
  • Female patients of child bearing potential must use an effective method of birth control (i.e. hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) during treatment period and 6 months thereafter.
  • Males must use an effective method of birth control during treatment period and 6 months thereafter.

Exclusion Criteria:

  • Any significant medical condition or laboratory abnormality unrelated to PTCL, or psychiatric illness that would prevent the patient from participating in the study and from signing the informed consent form;
  • Any condition that confounds the ability to interpret data from the study;
  • Other types of lymphomas, e.g. B-cell lymphoma;
  • Central nervous system and/or meningeal involvement by PTCL;
  • Signs or symptoms of Progressive Multifocal Leukoencephalopathy;
  • Preexistent peripheral neuropathy ≥ grade 2, whatever the cause;
  • Contraindication to any drug contained in the chemotherapy regimen;
  • Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin;
  • Subjects with HIV or HTLV1 positivity;
  • Subjects with active hepatitis B or C. Chronic carriers of hepatitis B without hepatitis B virus (HBV) DNA positive blood are eligible. Subjects with non-active hepatitis C (with normal transaminases) are eligible;
  • Chronic or acute, clinically significant, untreated bacterial, viral or fungal infection;
  • Any of the following laboratory abnormalities:

    1. Absolute neutrophil count (ANC) < 1500 cells/mm3 (1.5 x 109/L);
    2. Platelet count <75,000/mm3 (75 x 109/L);
    3. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3.0 x upper limit of normal (ULN). AST or ALT may be elevated up to 5 x ULN if their elevation can be ascribed to the presence of hematologic/solid tumor in the liver;
    4. Serum total bilirubin > 1.5 x ULN;
    5. Serum lipase level > 2 x ULN;
    6. Serum creatinine > 2.0 mg/dL and/or creatinine clearance or calculated creatinine clearance < 40 mL/minute;
    7. Hemoglobin < 8g/dL;
  • Active malignancies other than PTCL requiring systemic treatment;
  • Previous treatment with brentuximab vedotin;
  • Previous treatment with gemcitabine;
  • Pregnant or lactating females or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study;
  • Known history of any of the following cardiovascular conditions:

    1. Myocardial infarction within 2 years of enrollment
    2. New York Heart Association (NYHA) Class III or IV heart failure
    3. Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
    4. Recent evidence (within 6 months before first dose of study drug) of a left-ventricular ejection fraction <50%
  • Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives of last dose of that prior treatment;
  • Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03496779


Contacts
Layout table for location contacts
Contact: Marion BONHOMME +33 4 72 66 93 33 marion.bonhomme@lysarc.org

Locations
Layout table for location information
Belgium
ZNA Stuivenberg Recruiting
Antwerpen, Belgium, 2060
Contact: Ka Lung WU, MD         
A. Z. Sint-Jan Recruiting
Bruges, Belgium, 8000
Contact: Sylvia SNAUWAERT, MD         
Clinique Universitaire Saint LUC Recruiting
Brussels, Belgium, 1200
Contact: Eric VAN DEN NESTE, Pr         
Institut Jules Bordet Recruiting
Brussels, Belgium
Contact: Marie MAEREVOET, MD         
ULB Hôpital Erasme Recruiting
Brussels, Belgium
Contact: Virginie DE WILDE, MD         
UZ Gent Recruiting
Gent, Belgium, 9000
Contact: Fritz OFFNER, MD         
CHU de Liege Recruiting
Liege, Belgium, 4000
Contact: Christophe BONNET, MD         
CHU UCL Namur Recruiting
Yvoir, Belgium
Contact: Marc ANDRE, MD         
France
IHBN - CHU Cote de Nacre Recruiting
Amiens, France, 80054
Contact: Ghandi DAMAJ, MD         
CHU d'Amiens Recruiting
Amiens, France
Contact: Caroline DELETTE, MD         
CHU Angers Recruiting
Angers, France, 49033
Contact: Marie-Pierre MOLES-MOREAU, MD         
CH d'Avignon - Hôpital Henri Dufaut Recruiting
Avignon, France, 84000
Contact: Hacene ZERAZHI, MD         
CH Côte Basque Recruiting
Bayonne, France, 64100
Contact: Anne BANOS, MD         
CHU de Besançon - Hôpital Jean Minjoz Recruiting
Besançon, France, 25030
Contact: Adrien CHAUCHET, MD         
CH Chambéry Recruiting
Chambery, France, 73011
Contact: Maya Hacini, MD         
CHU d'Estaing Recruiting
Clermont-Ferrand, France, 63000
Contact: Sebastien BAILLY, MD         
APHP - Hopital Henri Mondor Recruiting
Creteil, France, 94010
Contact: Jehan DUPUIS, MD         
CHU de Dijon - Hôpital le Bocage Recruiting
Dijon, France, 21000
Contact: Olivier CASASNOVAS, MD         
CHU Grenoble Recruiting
Grenoble, France, 38043
Contact: Remy GRESSIN, MD         
CH de Versailles - Hopital André Mignot Recruiting
Le Chesnay, France, 78157
Contact: Hassan Farhat, MD         
CH du Mans Recruiting
Le Mans, France, 72000
Contact: Kamel LARIBI, Dr         
CHRU de Lille - Hôpital Claude Huriez Recruiting
Lille, France
Contact: Franck MORSCHHAUSER, Pr         
CHU de Limoges Recruiting
Limoges, France
Contact: Arnaud JACCARD, MD         
Centre Leon Berard Recruiting
Lyon Cedex 8, France, 69373
Contact: Emmanuelle NICOLAS-VIRELIZIER, MD         
Institut Paoli Calmettes Withdrawn
Marseille, France, 13000
Centre Hospitalier Annecy Genevois Recruiting
Metz-Tessy, France, 74374
Contact: Nicolas DAGUINDAU, MD         
CH Saint-Eloi Recruiting
Montpellier, France, 34295
Contact: Guillaume CARTRON, MD    04 67 33 83 62      
Principal Investigator: Guillaume CARTRON, MD         
CH de Mulhouse Sud Alsace Recruiting
Mulhouse, France, 68070
Contact: Bernard DRENOU, MD         
CHU Nancy - Brabois Recruiting
Nancy, France, 54511
Contact: Pierre Feugier, MD         
CHU de Nantes - Hôtel Dieu Recruiting
Nantes, France, 44093
Contact: Steven LE GOUILL, Pr         
APHP - Hôpital Saint Louis Recruiting
Paris Cedex 10, France, 75475
Contact: Catherine Thieblemont, MD         
APHP - Hôpital Necker Recruiting
Paris, France, 75015
Contact: Richard Delarue, MD         
Centre François Magendie - Hôpital du Haut Lévêque Recruiting
Pessac, France, 33604
Contact: Kamal BOUABDALLAH, MD         
Centre Hospitalier Lyon Sud Recruiting
Pierre Bénite, France, 69495
Contact: Emmanuel BACHY, MD         
CHU de Poitiers - Hôpital de la Milétrie Recruiting
Poitiers, France, 86021
Contact: Vincent DELWAIL, MD         
CHU De Rennes Recruiting
Rennes, France, 35033
Contact: Thierry LAMY DE LA CHAPELLE, MD         
Centre Henri BECQUEREL Recruiting
Rouen, France, 76038
Contact: Hervé TILLY, Pr         
CHU de Toulouse Recruiting
Toulouse, France, 31059
Contact: Loïc Ysebaert, MD         
CHRU de Tours Recruiting
Tours, France, 37044
Contact: Emmanuel Gyan, MD         
CH de Valenciennes Recruiting
Valenciennes, France, 59322
Contact: Sabine TRICOT, MD         
Sponsors and Collaborators
The Lymphoma Academic Research Organisation
Investigators
Layout table for investigator information
Study Chair: Richard DELARUE, MD APHP - Hôpital Necker
Study Chair: Olivier TOURNILHAC, MD CHU Estaing - Clermont Ferrant

Additional Information:
Layout table for additonal information
Responsible Party: The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier: NCT03496779     History of Changes
Other Study ID Numbers: TOTAL
First Posted: April 12, 2018    Key Record Dates
Last Update Posted: June 20, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by The Lymphoma Academic Research Organisation:
Brentuximab Vedotin
T-cell lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Gemcitabine
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs